Myriad Genetics Inc. (MYGN)

MYGN (NASDAQ:Diversified Services)
$32.93
neg -0.20
-0.60%
Today's Range: 32.73 - 33.43 | MYGN Avg Daily Volume: 1,156,700
Last Update: 05/17/13 - 4:00 PM EDT
Volume: 1,685,179
YTD Performance: 21.58%
Open: $33.25
Previous Close: $33.13
52 Week Range: $22.02 - $34.70
Oustanding Shares: 79,654,860
Market Cap: 2,638,965,512
6-Month Chart
TheStreet Ratings Grade for MYGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 7 7 7
Moderate Buy 1 1 1 1
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.18 2.00 2.00 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 09/12/00
Price Earnings Ratio: 21.10
Price Earnings Comparisons:
MYGN Sector Avg. S&P 500
21.10 21.00 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
35.83% 27.19% 78.12%
GROWTH 12 Mo 3 Yr CAGR
Revenue 23.40 0.52 0.15
Net Income 11.40 -0.18 -0.06
EPS 18.20 0.46 0.13
Earnings for MYGN:
EBITDA 0.19B
Revenue 0.50B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (06/13) FY (06/14)
Average Estimate $0.43 $0.43 $1.66 $1.86
Number of Analysts 9 4 8 8
High Estimate $0.45 $0.45 $1.68 $2.00
Low Estimate $0.40 $0.37 $1.65 $1.60
Prior Year $0.34 $0.36 $1.30 $1.66
Growth Rate (Year over Year) 25.82% 18.75% 28.08% 11.71%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
ostercywriter
ostercywriter: The Angelina Jolie Connection: The Debate Over Patenting Human Genes $MYGN $GNTLF $GE http://t.co/mFkZQvmGW0 via @minyanville
10 hours ago from Tweet Button
StockSignaling
StockSignaling: 25 Stocks To Watch: http://t.co/Vtx6dLy0Nw : $FANG $STZ $ERF $BSX $WCRX $ABCO $MYGN $SREV $FST $PRLB $CONN $MGM $TC $NWSA $XOMA #daytrading
11 hours ago from Stock Signaling
StockSignaling
StockSignaling: Movers and Shakers: Recently Upgraded: $NOC $ALTR $FANG $APO $SREV $EIX $FST $LPSN $TC $XOMA $JAZZ $VCLK $MYGN $DVN $SNTA #analyst #dow
13 hours ago from Stock Signaling
SeekingAlpha
SeekingAlpha: Myriad Genetics: Disruptive Products For Cancer Diagnostics http://t.co/n9puwIkf9r $MYGN
14 hours ago from Seeking Alpha
trends_trader
trends_trader: Would be pathetic if a link is established between #Brangelina #Jolie and gene patent companies like $MYGN. The human gene is public domain.
1 day ago from web
StockSignaling
StockSignaling: Movers and Shakers: Recently Upgraded: $NOC $ALTR $FANG $APO $SREV $EIX $FST $LPSN $TC $XOMA $JAZZ $VCLK $MYGN $DVN $SNTA #trading #dow
2 days ago from Stock Signaling
GREENskywater
GREENskywater: RT @gohsuket: アンジェリーナ ジョリー記事により米で遺伝子特許で癌テストを唯一独占するMyriad社の株↑ RT @MarketWatch Angelina Jolie star power extends to stock http://t.co/KrmLwhzZyP $MYGN
2 days ago from Twitter for Android
StockSignaling
StockSignaling: Movers and Shakers: Recently Upgraded: $NOC $ALTR $FANG $APO $SREV $EIX $FST $LPSN $TC $XOMA $JAZZ $VCLK $MYGN $DVN $SNTA #markets #nasdaq
2 days ago from Stock Signaling
StockSignaling
StockSignaling: Upgraded Stocks Trading in a New Range: $NOC $BEAM $FANG $ALTR $APO $URI $BMR $GVA $MYGN $ABCO $PCP $FST $XOMA $AWK $RAX #finance #markets
2 days ago from Stock Signaling
nnn1na
nnn1na: RT @jolshan: Angelina Jolie not only raised awareness about genetic testing, she also raised stock prices: http://t.co/ppbc8u2lhp $MYGN
2 days ago from Twitter for iPad

Earnings Roundup Real Money Pro($)

By

Doug Kass

| May 08, 2013 | 10:18 AM EDT
Here is my compilation of last night's profit reports.
Bearish
Myriad Genetics numbers cut at Credit Suisse
Mar 04, 2013 | 8:22 AM EST
Shares of MYGN now seen reaching $28, according to Credit Suisse. Estimates also reduced, given lower Medicare reimbursement rates. Neu...
Bearish
Myriad Genetics downgraded at JP Morgan
Jan 03, 2013 | 8:22 AM EST
MYGN was downgraded to Underweight, JP Morgan said. Supreme Court ruling on ACLU case may hang over the stock. 

Tough Trading in a Wobbly Market

By

Ken Shreve

| Dec 06, 2012 | 11:30 AM EST
At least the uptrend is still intact.
Bullish
Myriad Genetics upgraded at BofA/Merrill
Oct 24, 2012 | 8:09 AM EDT
MYGN was upgraded from Neutral to Buy, Bank of America/Merrill Lynch said. $32 price target. Company can continue to diversify and expa...
Update
Myriad Genetics rated new Neutral at Credit Suisse
Sep 25, 2012 | 8:21 AM EDT
MYGN was initiated with a Neutral rating, Credit Suisse said. $28 price target. Near and long term concerns overshadow underlying organ...
Bullish
Myriad Genetics upgraded at Leerink
May 21, 2012 | 8:13 AM EDT
MYGN was upgraded from Market Perform to Outperform, Leerink Swann said. Reimbursement and IP fears appear overdone. 
Update
Myriad Genetics rated new Neutral at BofA Merrill
May 11, 2012 | 7:53 AM EDT
MYGN was initiated with a Neutral rating, Bank of America Merrill Lynch said.  $28 price target.  Shares appear fairly valued...
Bullish
Myriad Genetics numbers raised at Oppenheimer
May 02, 2012 | 7:58 AM EDT
Shares of MYGN now seen reaching $29, Oppenheimer said. Estimates also raised on another solid beat and raise. Perform rating.

Our Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.